• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Neurotechnology Industry 2006 Report - Market Analysis and Strategic Investment Guide for the Global Neurological Disease and Psychiatric Illness Markets

Posted on: Wednesday, 21 June 2006, 06:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c19099) has announced the addition of the new NeuroInsights report "The Neurotechnology Industry 2006" to their offering.

According to NeuroInsights, Neurological diseases and psychiatric illnesses represent the largest and fastest growing unmet medical market: 1.5 billion people worldwide. Building on decades of brain research and the success of the Human Genome Project, neurotechnology companies hold the greatest potential for major scientific discoveries, commercial success and sustainable investment opportunities.

The neurotechnology industry includes companies researching, developing and marketing pharmaceuticals, biologics, medical devices, as well as diagnostic and surgical equipment for the treatment of neurological and psychiatric illnesses.

NeuroInsights has identified three sectors within the $110 billion industry:

neuropharmaceuticals, neurodevices and neurodiagnostics. Neurotechnology companies face fundamentally different investment requirements, research and development challenges, regulatory milestones and social drivers that sets them apart from other life science and health care companies.

The Neurotechnology Industry 2006(TM) is the first report to provide a unified market-based framework to help investors, companies, and governments easily quantify opportunities, determine risks and understand the dynamics of this rapidly growing market.

This framework helps answer critical investment questions, such as:

-- What are the therapeutic development strategies and clinical pipelines in Alzheimer's? Pain? Stroke? Addiction? Depression?

-- What are the current IPO, acquisition and licensing valuations?

-- What are the fastest growing markets for neurodevices?

-- What impact is neuroimaging having on drug development and disease diagnosis?

-- Who is investing in neurotech and what companies are getting funded?

Report Highlights

-- Profiles of 450 public and private neurotech companies

-- Competitive analysis and clinical trials for 15 disorders, including Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, obesity, pain, Parkinson's, schizophrenia, sleep and stroke

-- The NeuroInsights' Neurotech Index(TM): an investment benchmark that measures the stock performance of 30 publicly traded neurotechnology companies

-- Profiles of the 10 most active neurotech venture capital firms, including investments by market segment

-- Extensive discussion of the specific technological, demographic, regulatory, and intellectual property trends driving the global neurotech industry

-- Analysis of the biological causes; current treatment options, emerging therapeutic strategies, and compounds in clinical trials by company, mechanism of action, and stage of development for each indication

Some companies mentioned in the report include:

4-D NeuroImaging, Abbott Laboratories, Abmaxis, Acadia Pharmaceuticals, Accera, Inc., Acorda Therapeutics, Acta Vascular, AcuFocus, Acumen Pharmaceuticals, Addex Pharmaceuticals, Adenosine Therapeutics, Aderis Pharmaceuticals, Adlyfe, Adolor Corporation, Advanced Bionics, Aegera Therapeutics, AGY Therapeutics, Aspect Medical Systems, Aspreva Pharmaceuticals, AstraZeneca, Astro-Med, Athena Diagnostics, Athersys, Avera Pharmaceuticals, Avicena Group, Avigen, Axaron Bioscience, AxoGen, Axon Neuroscience, Axonyx, Azevan, Bayhill Therapeutics, BioArctic Neuroscience, BioAxone Therapeutics, BioControl Systems, Biocortech

BioFrontera, Cellzome AG, CeNeS Pharmaceuticals, Cephalon, Ceptor Corp., Cerebral Vascular Applications, Cerebricon, Ltd., Ceregene, Chiesi Farmaceutici, Chondrogene, Chronogen, Clarus Medical, Clera, Cleveland Medical Devices, CNS Response, CoAxia, Cochlear, Ltd., Cognetix, Cognitive Pharmaceuticals, Cognosci

CogState, Ltd., Compumedics, Ltd., Computer Technology & Imaging (CTI), Concentric Medical, ConMed, Corcept Therapeutics, Cordis, Cortech Solutions

Cortex Pharmaceuticals, CPS Innovations (part of CTI), CTI Molecular Imaging, Inc.

Curidium, Curis, Cyberkinetics Neurotechnology Systems, Cyberonics, Cypress Bioscience, Cytrx, DarPharma, Descartes Therapeutics, DOV Pharmaceutical, D-Pharm, Ltd., DrugAbuse Sciences, Durect Corp., Dynogen Pharmaceuticals, Eisai Company, Ltd., Elan, Electrical Geodesics, Elekta, Eli Lilly, Epic Biosonics

EpiCept Corp., Epoch Innovations, ESPLORA, Ester Neurosciences, ev3, Everest Biomedical Instruments, Evotec Neurosciences, ExonHit Pharmaceuticals SA

Eyetech Pharmaceuticals, Faust Pharmaceuticals, mmusol, Indevus Pharmaceuticals, Ingenium Pharmaceuticals, Innercool Therapies, Kaleidos Pharma, Kinexis

Knopp Neurosciences, Kosei, Krenitsky Pharmaceuticals, Marinus Pharmaceuticals

MedCool, Inc, MED-EL, Medimod Research Institute, MedImpulse, MediVance

Medivation, MedPointe Pharmaceuticals, Neuralynx, Neuraxo Biotec GmbH, Neuraxon, Neuren Pharmaceuticals Limited, Neurome, NeuroMed Technologies, NeuroPhysics, NeuroRecovery, Neuroscan, Optima Neuroscience, Optobionics

Organon, Palatin Technologies, Purdue Pharma, Questcor Pharmaceutical, Radiant Medical, Selva Medical, Senexis, Sention, TorreyPines Therapeutics, Touch EMAS, Ltd., Transition Therapeutics, Wellstat Therapeutics, Wyeth, Xcel Pharmaceuticals, Xenome, Ltd., Xenoport, Xenova Group, Xention Discovery, Ltd., Xsira Pharmaceuticals, Xytis Inc, Yaupon Therapeutics, Zynex Medical

For more information visit (http://www.researchandmarkets.com/reports/c19099)

Source: Business Wire

More News in this Category